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Abstract 
Background: Age‑associated changes in genomic DNA methylation have been primarily attributed to 5‑methylcy‑
tosine (5mC). However, the recent discovery of 5‑hydroxymethylcytosine (5hmC) suggests that this epigenetic mark 
might also play a role in the process.
Methods: Here, we analyzed the genome‑wide profile of 5hmc in mesenchymal stem cells (MSCs) obtained from 
bone‑marrow donors, aged 2–89 years.
Results: We identified 10,685 frequently hydroxymethylated CpG sites in MSCs that were, as in other cell types, sig‑
nificantly associated with low density CpG regions, introns, the histone posttranslational modification H3k4me1 and 
enhancers. Study of the age‑associated changes to 5hmC identified 785 hyper‑ and 846 hypo‑hydroxymethylated 
CpG sites in the MSCs obtained from older individuals.
Conclusions: DNA hyper‑hydroxymethylation in the advanced‑age group was associated with loss of 5mC, which 
suggests that, at specific CpG sites, this epigenetic modification might play a role in DNA methylation changes during 
lifetime. Since bone‑marrow MSCs have many clinical applications, and the fact that the epigenomic alterations in 
this cell type associated with aging identified in this study could have associated functional effects, the age of donors 
should be taken into account in clinical settings.
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Background
Epigenetic mechanisms such as DNA methylation are 
implicated in many different biological processes, such as 
regulation of chromatin structure, X chromosome inac-
tivation, gene imprinting, and genomic instability [1–3]. 
It is well known that genomic DNA methylation is modi-
fied during the lifetime of higher organisms [4], and this 
variation has been regularly ascribed to the epigenetic 
mark 5-methylcytosine (5mC) [5–8]. However, the recent 
discovery of the presence of 5-hydroxymethylcytosine 
(5hmC) in DNA implies that this epigenetic mark should 
also be taken into account in studies of DNA methylation 
and aging.
5hmC is an epigenetic modification originated through 
the oxidation of 5-methylcytosine by the Ten-eleven 
Translocation (TET) family of proteins [9, 10]. It was 
identified for the first time in mammals 40  years ago 
[11], and recent studies have shown high levels of this 
chemical modification in mouse Purkinje and granule 
neurons [12]. TET proteins also catalyze the conversion 
of 5hmC into 5-formylcytosine (5fC) and 5-carboxylcyto-
sine (5caC) through consecutive oxidations [13], both of 
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which are substrates for thymine-DNAglycosylase (Tdg), 
finally yielding unmethylated cytosine [14]. While the 
low affinity of the maintenance methyltransferase DNA 
methyltransferase 1 (DNMT1) for 5hmC during cell divi-
sion [15] might suggest that 5hmC is merely a transient 
DNA modification involved in DNA demethylation path-
ways [15–17], the tissue-specific distribution of this epi-
genetic mark [18, 19] together with its high levels in the 
brain and central nervous system [12] point to this epige-
netic modification having its own biological role. While 
hydroxymethylation of 5mC has been linked to the pro-
cesses of demethylation during biological processes, such 
as primordial germ cells and zygotic development [20], 
several studies have associated 5hmC with transcrip-
tional activation mediated by enhancers, both in embry-
onic and differentiated cells [21–25]. The functional role 
of 5hmC takes on greater importance given the fact that 
it is deregulated in various human pathologies such as 
cancer, and degenerative diseases like Parkinson’s and 
Alhzeimer’s [26, 27].
Many approaches commonly used to measure 5mC, 
such as conventional bisulfite modification, are in fact 
not able to distinguish between 5mC and 5hmC [28]. 
However, the development of new approaches, such 
as those based on the oxidation of genomic DNA with 
potassium perruthenate, a compound able to selec-
tively oxidize 5hmC to 5fC, which is then converted 
to uracile by sodium bisulfite [29], have been a break-
through in the study of the biological functions of 
5hmC. This new possibility for analyzing the distribu-
tion of 5hmC and changes in its levels during different 
cellular processes will help to elucidate its biological 
role. For instance, recent genome-wide 5hmC stud-
ies have revealed that it may be enriched in distinct 
genomic regions, such as gene bodies, promoters, and 
distal regulatory regions in differentiated and embry-
onic stem cells [22, 24, 30].
Previous work from our laboratory has described a 
global loss of DNA methylation in bone-marrow mes-
enchymal stem cells (MSCs) during aging [5]. In a con-
tinuation of this research, our current contribution aims 
to characterize the genome wide DNA hydroxymethyla-
tion status of MSCs, obtained from bone-marrow donors 
aged from 2 to 89 years, using the above mentioned oxi-
dation-based technique [29] followed by HumanMeth-
ylation 450K BeadChip arrays (Illumina®). On the one 
hand, our study provides information about the genomic 
location of 5hmC in adult stem cells, which has not 
been described previously, and on the other, we analyze 
changes in 5hmC in MSCs during aging, and their pos-
sible relationship with 5mC changes. Since bone-marrow 
MSCs can be used in many clinical therapies [31], the 
molecular characterization of these type of cells could 
facilitate the development of safe therapies for human 
diseases.
Methods
Isolation and culture of MSCs
MSCs were obtained from young (n: 11) and older (n: 6) 
bone-marrow donors. After acquiring informed consent, 
bone-marrow aspirates were obtained from the young 
patients and, from a second group, bone scrapings were 
obtained following hip replacement surgery. Mononu-
clear cells were isolated by Ficoll density centrifugation 
(400g, 25  min, 20  °C), washed twice by sedimentation 
with phosphate buffer (300g, 5  min) and the cells re-
suspended in MSC medium (DMEM plus 10 % FBS) and 
seeded into culture flasks (Nunc, Roskilde, Denmark) at 
1.5 × 105 cells/cm2 and allowed to adhere for 24 h. MSCs 
were then cultured (37  °C, 5  % CO2) in MSC medium. 
DNA methylation and hydroxymethylation analyses were 
carried out at cell passages 4–7 (Additional file 1: Table 
S1). The study was approved by the Ethics Committee of 
Clinical Research at Hospital Universitario Niño Jesús 
and Hospital U.M. Valdecilla, and written informed con-
sent was obtained from patients and parents/tutors.
Genome‑wide DNA methylation analysis with high‑density 
arrays
Microarray-based DNA methylation profiling was per-
formed with the HumanMethylation 450 BeadChip 
[32]. Oxidative bisulfite (oxBS) and bisulfite-only (BS) 
conversion was performed using the TrueMethyl® pro-
tocol for 450K analysis (Version 1.1, CEGX) following 
the manufacturer’s recommended procedure. Processed 
DNA samples were then hybridized to the BeadChip 
(Illumina), following the Illumina Infinium HD Meth-
ylation Protocol. Genotyping services were provided by 
the Spanish “Centro Nacional de Genotipado” (CEGEN-
ISCIII) (http://www.cegen.org).
HumanMethylation450 BeadChip data preprocessing
Raw IDAT files were processed using the R/Bioconduc-
tor package minfi (version 1.12.0). The SWAN algorithm 
[33] was used to correct for differences in the microar-
ray probe designs. No background correction or control 
probe normalization was applied. Probes where at least 
two samples had detection p values  >0.01, and samples 
where at least 5500 probes had detection p values >0.01 
were filtered out. M values and beta values were com-
puted as the final step of the preprocessing procedure.
Batch effect correction
In order to detect whether there was any batch effect 
associated with technical factors, multidimensional scal-
ing (MDS) was employed as a visualization technique 
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to highlight any unusual interaction affecting the differ-
ent samples. The posterior adjustment of the samples 
was performed by means of the ComBat method imple-
mented in the R/Bioconductor sva package (version 
3.12.0). The variables Sample_ID and Oxidated_Status 
were used as covariates of interest, while the experiment 
number was employed as the main batch covariate.
Computation of hydroxymethylation levels
Beta values from oxidized samples were subtracted from 
their corresponding non-oxidized pair (Δß), generating 
an artificial dataset representing the level of 5hmC for 
each probe for each sample [34]. Two further datasets 
were created to represent 5mC and total methylation lev-
els, using beta values from oxidized and normal samples, 
respectively.
Detection of differentially methylated 
and hydroxymethylated probes
For the three main datasets, samples were split into two 
groups: young (ages ranging from 2 to 29; n: 11) and old 
(aged between 63 and 89; n: 6) individuals. For each of 
the probes in every dataset, a Wilcoxon non-parametric 
test was used to detect any significant change in meth-
ylation and hydroxymethylation with respect to age 
group. The set of p values <0.05 obtained from the tests 
was further adjusted for multiple comparisons using the 
Benjamini-Hochberg method to control for false discov-
ery rate (FDR < 0.25) in the identification of differentially 
methylated and hydroxymethylated probes. An addi-
tional threshold of shift size was applied, filtering out the 
30  % of those probes with the smallest average change 
between age groups.
Identification of hydroxymethylated probes
5hmC levels were employed to generate a set of probes 
representing the regions where this mark was located. 
Probes having a hydroxymethylation level above 0.1 in at 
least 50 % of the samples were selected as candidates.
Histone enrichment analysis
In order to analyze the enrichment of histone marks 
on a subset of probes, we used the information con-
tained in the UCSC Genome Browser Broad Histone 
track from the ENCODE Project. Histone mark peaks 
were downloaded for every combination of cell line and 
antibody. For each track, a 2 × 2 contingency table was 
built to represent the portion of the whole set of possi-
ble probes in the microarray with respect to member-
ship of the subset of interest, and any overlap between 
probes and histone peaks. A Fisher’s exact test was used 
to determine whether there was a significant enrichment 
of the selected histone mark in the subset of interest. P 
values were adjusted for multiple comparisons using the 
Benjamini-Hochberg method to control the FDR. A sig-
nificance level of 0.05 was used to determine whether 
combinations of each histone mark and cell line showed 
significant changes in proportion of enrichment. Addi-
tionally, the base-2 logarithm of the odds ratio (OR) was 
used as a measure of shift size.
Chromatin segment enrichment analysis
Data representing the results from the Broad Chrom-
HMM Project were downloaded from the UCSC 
Genome Browser site. Each of the tracks in this data-
set represents a different segmentation generated by a 
Hidden Markov Model (HMM) with chromatin immu-
noprecipitation sequencing (ChIP-Seq) signals from 
the Broad Histone Project as inputs. The segmenta-
tions were later curated and labeled according to their 
functional status [35, 36]. In order to detect significant 
enrichment in the proportion of probes in a given sub-
set of interest belonging to a functional category, an 
analysis strategy similar to that employed for the detec-
tion of histone enrichment was performed, although in 
this case, a 2 × 2 contingency table was built using func-
tional status as the basis of segmentation rather than 
different antibodies. Fisher’s exact test was employed 
to identify enrichment. Significant combinations were 
detected using an FDR (Benjamini-Hochberg proce-
dure) threshold of 0.05. The base-2 logarithm of the OR 
was used as a measure of shift size.
Genomic region analysis
The probes in the microarray were assigned a genomic 
region according to their position relative to the tran-
script information extracted from the R/Bioconductor 
package TxDb.Hsapiens.UCSC.hg19.knownGene (pack-
age version 3.0.0). A probe was said to be in a Promoter 
region if it was located in a region up to 2 kb upstream of 
the transcription start site (TSS) of any given transcript. 
Similarly, a set of mutually exclusive regions were defined 
within the transcripts, namely 5UTR, 3UTR, First Exon, 
Exon and Intron. A probe could belong to only one of 
these categories, and if the probe overlapped with two 
or more of those regions in different transcripts it was 
assigned to the region with the higher level of prece-
dence (as dictated by the order stated above). If a probe 
was not assigned to any of these special regions, it was 
labeled by default as Intergenic. A contingency table was 
built for each of the subsets, partitioning the whole set of 
probes according to the genomic region they belonged to 
and the subset of interest. A Pearson’s χ2 test was used to 
determine if there was a significant change in proportion 
between the number of probes marked as belonging to a 
given region inside and outside the subset of interest. A 
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significance level of 0.05 and the shift size, as measured 
by the OR, were used for this test.
CGI status analysis
As for the genomic region analysis, probes were labeled 
according to their position relative to CpG-islands (CGI). 
The CGI locations used in the analyses were obtained 
from the R/Bioconductor package FDb.InfiniumMeth-
ylation.hg19 (package version 2.1.999). The procedure 
for generating these CGIs is described by Wu et al. [37]. 
“CpG shores” were defined as the 2  kbp regions flank-
ing a CGI. “CpG shelves” were defined as the 2  kbp 
regions either upstream or downstream from each CpG 
shore. Probes not belonging to any of these regions were 
assigned to the special category “non-CGI”. Each probe 
was assigned to only one of the categories. A 4 × 2 con-
tingency table was constructed for every subset of probes 
to study the association between the given subset and 
the different CGI categories. A χ2 test was used to deter-
mine if any of the categories had a significant association 
with the given subset. For each of the CGI status levels, a 
2 × 2 contingency table was defined and another χ2 test 
was used to independently evaluate the association of the 
given subset with each status level, a significance level of 
0.05 being used for all tests. Shift size was reported as the 
OR for each of the individual tests.
Density of CpG analysis
For each of the probes in the HumanMethylation450 
microarray, density of CpG was measured as the num-
ber of “CG” 2-mers present divided by the number of 
those possible in a 2  kbp window centered on the CpG 
under study. A Wilcoxon non-parametric test was used 
to determine if there was a significant difference between 
the densities of the CpGs belonging to each subset of 
interest and the densities of the array probes in the back-
ground. A significance level of 0.05 was employed for all 
tests. Shift size was measured using Cliff ’s Delta (D).
Gap distance analysis
Distance to both the centromere and telomere was 
measured for each of the probes in the HumanMeth-
ylation450 microarray. In order to find significant differ-
ences between the probes within the subset of interest 
and those in the background, a Wilcoxon non-paramet-
ric test was used. Again, a significance level of 0.05 was 
employed for all tests, and Cliff ’s Delta (D) was used as a 
measure of shift size.
Microarray background correction
Although it is sometimes referred to as a genome-
wide solution, the HumanMethylation450 BeadChip 
only covers a fraction of the entire genome. In its 27K 
predecessor, the probes were mainly located at gene pro-
moter regions, while in addition to the promoter probes, 
the HumanMethylation450 BeadChip includes probes 
located inside genes and in intergenic regions [38].
The irregular distribution of probes can lead to 
unwanted bias when studying whether a selected sub-
set of probes is enriched with respect to any functional 
or clinical mark. A reference to the background distri-
bution of features was included in every type of statisti-
cal test performed in order to prevent our conclusions 
being driven by the irregular distribution of probes. In 
qualitative tests (CGI status, genomic region, and histone 
mark enrichment), the contingency matrix was built to 
represent the background distribution of the microar-
ray. In quantitative tests (CpG distance to centromeres 
and telomeres) the corresponding metric was compared 
between the subset of interest and the remaining probes 
in the microarray. Thus, any significant result would indi-
cate a departure from the fixed background distribution 
and ignore any manufacturer bias [39].
Circos data track smoothing
In order to plot the CpG information on a Circos 
genome-wide graphs [40], smoothing was applied to our 
data. Broad histone peak information from the UCSC 
Genome Browser was averaged by dividing the genome 
into intervals of 100  kbp and assigning each with score 
corresponding to the average of the broad peak scores 
found within it. CpG locations were enlarged to 200 kbp 
regions centered on the CpG in order to enhance the 
visualization.
Gene ontology analysis and annotation
Probe subsets were converted to gene subsets using the 
annotation information from the R/Bioconductor pack-
age TxDb.Hsapiens.UCSC.hg19.knownGene [Carlson 
M. TxDb.Hsapiens.UCSC.hg19.knownGene: Annotation 
package for TxDb object(s)]. A probe was assigned to a 
gene if it was located within one of the genomic regions 
represented by the different transcripts belonging to that 
gene, or in a 2  kbp region upstream of the correspond-
ing TSS. Probes converted in this way can be assigned to 
zero (i.e. intergenic probes) or multiple genes. After gene 
conversion, each subset of interest was analyzed using 
the HOMER software tool [41] configured to use the full 
set of genes represented in the HumanMethylation450 
architecture as a background. HOMER tested the genes 
in each subset of interest against 21 different databases, 
including the gene ontology (GO) for biological process.
Bisulfite pyrosequencing
DNA hydroxymethylation patterns of representative CpG 
sites differentially 5-hydroxymethylated (d5hmC) during 
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aging were analyzed by bisulfite pyrosequencing in 11 of 
the 17 MSC samples obtained from individuals of differ-
ent ages (Additional file 1: Table S1). Oxidative bisulfite 
(oxBS) and bisulfite-only (BS) conversion was carried 
out according to the TrueMethyl® Array Kit User Guide 
(CEGX, Version 2) with some modifications. Briefly, 
DNA samples were cleaned using Agencourt AMPure 
XP (Beckman Coulter), and then oxidized with 1  μL of 
a KRuO4 (Alpha Aeser) solution (375  mM in 0.3  M 
NaOH). Finally, BS conversion was performed using Epi-
tect bisulfite kit (Qiagen®).
The set of primers for PCR amplification and sequenc-
ing were created using the specific software PyroMark 
assay design (version 2.0.01.15) and designed to hybrid-
ize with CpG free sites to ensure methylation independ-
ent amplification (Additional file 2: Table S2). After PCR 
amplification of the region of interest with the specific 
primers, pyrosequencing was performed using PyroMark 
Q24 reagents, and vacuum prep workstation, equipment 
and software (Qiagen®).
Data analysis workflow
All the necessary steps for upstream and downstream 
analyses were defined and implemented using the Snake-
make tool [42], which allows data scientists to generate a 
reproducible and inherently parallel processing pipeline. 
The source code of the workflow is included as Addi-
tional files.
Results
DNA hydroxymethylation profiling in MSCs
To study the genomic distribution of 5hmC in MSCs 
we determined the DNA methylation status of 479,423 
CpG sites in 17 independently isolated primary MSCs, 
obtained from individuals aged between 2 and 89  years 
(Additional file 1: Table S1).
We identified 134,693 hydroxymethylated CpG sites 
present in at least one of the 17 MSCs samples. Interest-
ingly, although the number of hydroxymethylated CpG 
sites per sample ranged from 15,761 to 42,392 (data not 
shown), only 10,685 (Additional file 3: Table S3) of these 
CpG sites were hydroxymethylated in more than 50 % of 
the samples. The genomic distribution of these frequently 
hydroxymethylated CpGs sites (FhmC sites) was charac-
terized compared to the CpG sites analyzed by the 450 k 
array.
FhmC sites were preferentially found at the low density 
CpG DNA regions interrogated by the array (Wilcoxon 
non-parametric test; p < 0.001, D = −0.47) (Fig. 1a, left). 
Consequently, these FhmC sites were most frequently 
found in non-CpG islands (non-CGIs) (Chi square test; 
p < 0.001, OR 3.62) and were impoverished in CGIs (Chi 
square test; p < 0.001, OR 0.21) with respect to all CpG 
sites (Fig.  1a, center). The gene location study showed 
that these FhmC sites were mainly found in introns (Chi 
square test; p  <  0.001, OR 1.63) and, at lower levels, at 
promoter regions (Chi square test; p  <  0.001, OR 0.55), 
5′UTR regions (Chi square test; p < 0.001, OR 0.35), first 
exon (Chi square test; p  <  0.001, OR 0.53), and exons 
(Chi square test; p < 0.001, OR 0.58) (Fig. 1a, right). With 
respect to centromeres and telomeres, the FhmC sites 
were farther away from them than the median in terms 
of other background sites (Wilcoxon non-parametric 
test; p < 0.001 for both measurements), although the size 
of these shifts was rather small (D = 0.01 and D = 0.06, 
respectively) (Fig. 1b).
To identify possible chromatin marks associated with 
FhmC sites in adult MSCs we compared them with pre-
viously published data on a range of histone modifica-
tions and chromatin modifiers in 11 different cell types 
(see “Methods” section) (Fig.  2a). We found statistically 
significant preferential associations (Fisher’s exact test; 
p  <  0.05) of FhmC sites with the active histone mark 
H3k4me1, and also with the repressive histone mark 
H3K9me3 (Fig.  2). A common set of “chromatin states” 
across seven human cell types were learned by computa-
tionally integrating ChIP-seq data for nine factors com-
bined with input from a Hidden Markov Model (HMM) 
(see “Methods” section). In total, fifteen states were used 
for the segmentation of the genome, which were then 
grouped and colored to highlight predicted functional 
elements. We found that FhmC sites were significantly 
associated with enhancers (Fisher’s exact test; p  <  0.05) 
(Fig. 2c).
Age‑associated changes in 5hmC and relationships 
with 5mC
To identify possible age-dependent changes in 5hmC in 
MSCs we compared the levels of this epigenetic modi-
fication in two age groups, one of young individuals 
(ages ranging from 2 to 29; n: 11) and another of those 
of advanced age (63–89  years; n: 6) (Additional file  1: 
Table S1), using a Wilcoxon non-parametric test (see 
“Methods” section). We identified 1631 CpG sites dif-
ferentially 5-hydroxymethylated (d5hmC) between the 
two groups (FDR < 0.25), of which 785 (48.13 %) gained 
hydroxymethylation (hyper5hmC) (Additional file  4: 
Table S4) and 846 (51.87  %) lost hydroxymethylation 
(hypo5hmC) (Additional file  5: Table S5) in the older 
age group (Fig. 3a). Hierarchical clustering of all samples 
using these d5hmC sites showed the correct classifica-
tion of each individual in their corresponding age group 
(Fig.  3b). The direct comparison of the hydroxymeth-
ylation levels of representative samples, i.e. the young-
est individual (2 years old) and the oldest (89 years old), 
identified thousands of differentially hydroxymethylated 
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CpG sites, albeit showing no net gain or loss of this epi-
genetic modification due to chronological age (Fig. 3c).
To validate the results obtained with the methylation 
arrays, we selected 2 of the sequences previously identi-
fied and analyzed their methylation status by bisulfite 
pyrosequencing in 11 MSCs obtained from individu-
als aged between 2 and 87  years old (Additional file  1: 
Table S1). The sequences selected corresponded to the 
potassium voltage-gated channel subfamily Q member 
1 (KCNQ1) gene, which become hyperhydroxymethyl-
ated with aging, and the von Willebrand factor A domain 
containing 2 (VWA2) gene, which become hypohydrox-
ymethylated. Bisulfite pyrosequencing confirmed the 
hydroxymethylation changes identified with the methyla-
tion arrays (Fig. 3d).
The analysis of the gene ontology (GO) of the genes 
associated with d5hmC showed that both hyper- and 
hypomethylated genes were significantly enriched 
(FDR  <  0.05) in specific GO terms of biological pro-
cesses related to development (Additional file  6: Table 
S6, Additional file  7: Table S7). While both hyper- and 
hypohydroxymethylated genes were associated with cell 
adhesion, those which were hyperhydroxymethylated 
were also related to morphogenesis (Additional file  6: 
Table S6), but hypohydroxymethylated genes were more 
strongly associated with differentiation (Additional file 7: 
Table S7).
To study the relationship between age-associated 
changes in 5mC and 5hmC, we compared d5hmC 
with CpG sites differentially 5-methylated (d5mC). We 
first identified 13,559 CpG sites with changed 5mC 
levels (FDR  <  0.25) of which, in the older age group, 
3708 (27.34  %) gained 5-methylcytosine (hyper5mC) 
and 9851 (72.65  %) lost it (hypo5mC). Interestingly, 
most of the CpG sites hyperhydroxymethylated with 
aging (54.52  %) overlapped with CpG sites which lose 
5-methylcytosine during aging (Fig. 3e). GO analysis of 
genes asociated with these common CpG sites showed 
significant enrichment (FDR  <  0.05) in specific GO 
terms of biological processes related to developmen-
tal aspects, and specifically to negative regulation of 
the cell cycle (Additional file 8: Table S8). On the other 
hand, despite a small percentage of probes which lost 
5hmC with age being associated with d5mC, no pref-
erential associations between hypo5hmC and either 
hyper- or hypo5mC were found (Fig.  3e). To study in 
detail the relationships between 5mC and 5hmC we 
performed the same analysis again, but this time tak-
ing into account CpG island status and genomic region 
(Additional file  9: Figure S1). In this manner, to study 
a
b
Fig. 1 Functional genomic analysis of 5hmC. a Left: Violin plot showing the distribution of CpG density for the frequently hydroxymethylated sites 
(FhmC) and the background sites in the Infinium HumanMethylation450 microarray (Wilcoxon non‑parametric test; p < 0.001, D = −0.47). Center: 
Stacked bar chart showing the relative proportions of CpG sites classified according to their CpG Island status in the frequently hydroxymethyl‑
ated and background sites (Chi square test; p < 0.001, OR 3.62). Right: Stacked bar chart describing the classification of FhmC and background sites 
according to their relative genomic location (Chi square test; p < 0.001, OR 1.63). b Violin plots showing the distances to centromeres (left) and 
telomeres (right) of the FhmC sites and background probes (Wilcoxon non‑parametric test; p < .01; D = 0.02 and p < .001; D = 0.06, respectively)
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the changes of 5hmC in promoters and CGI where clas-
sically 5mC have been found hypermethylated dur-
ing aging, we crossed referenced CpG sites identified 
in both groups, but no overlap worth mentioning was 
found (Additional file 9: Figure S1).
Genomic analysis of hyper5hmC and hypo5hmC CpG sites 
in the two age groups
To study the genomic characteristics of d5hmC in both 
age groups, we first determined the distribution of the 
hyper5hmC and hypo5hmC sites on the genome.
The distribution of d5hmC CpG sites in the two age 
groups showed that hypo5hmC sites were located in 
regions with low CpG density (Wilcoxon non-para-
metric test; p  <  0.001, D  =  −0.25) (Fig.  4a, left) and 
enriched in non-CGIs (Chi square test; p  <  0.001, OR 
2.09). Hyper5hmC sites, in contrast, were enriched 
in CGIs (Chi square test; p  <  0.001, OR 1.54) (Fig.  4a, 
center). With regard to gene location, hyper5hmC sites 
were enriched in introns (Chi square test; p < 0.001, OR 
1.36), in exons (Chi square test; p < 0.001, OR 1.78), and 
in 3′UTR regions (Chi square test; p  <  0.001, OR 1.62). 
a
b
c
Fig. 2 Chromatin signatures associated with DNA hydroxymethylation in MSCs. a Heatmap showing the relative enrichment of the frequently 
hydroxymethylated (FhmC) sites for several combinations between ENCODE Broad Histone project cell lines and histone marks. A red tile is drawn 
only if the 5hmC site is significantly enriched for the corresponding combination (Fisher’s exact test; p < 0.05); a white to red scale is used to 
represent the strength of the enrichment, using the base‑2 logarithm of the odds ratio (OR) as a measure of the shift size. b Upper: Circular layout 
of chromosomes 6 and 17. Outermost track: Tile chart describing the location of the FhmC sites. CpG locations were enlarged to 200 kbp regions 
centered on the site of interest to enhance the visualization. Middle and innermost tracks: Histogram charts showing the peak scores obtained from 
the Broad Histone UCSC data for H3k4me1 (middle) and H3k9me3 (innermost) averaged over 200 kbp regions. Lower: Genome diagrams showing the 
relative enrichment of H3k4me1 and H3k9me3 marks on two specific regions of chromosomes 17 (left) and 6 (right) and the FhmC sites. c Heatmap 
showing the relative enrichment of FhmC sites for given sets of combinations between ENCODE Broad ChromHMM project cell lines and chromatin 
states. A tile is drawn only if FhmC sites are significantly enriched for the corresponding combination (Fisher’s exact test; p < 0.05). Tile colors are 
chosen to resemble those used in the UCSC representation of the ChromHMM dataset. The intensity of the color is used to represent the strength of 
the enrichment, using the base‑2 logarithm of the OR as a measure of shift size
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Both hyper- and hypo5hmC sites were enriched in inter-
genic regions (Chi square test; p  <  0.001, OR 1.51 and 
p  <  0.001, OR 1.80, respectively), and impoverished in 
promoter regions (Chi square test; p < 0.001, OR 0.35 and 
p < 0.001, OR 0.72 respectively) and 5′UTR regions (Chi 
square test; p  <  0.001, OR 0.60 and p  <  0.001, OR 0.43 
respectively). Besides, hypo5hmC sites were depleted in 
first exons (Chi square test; p < 0.001, OR 0.53) (Fig. 4a, 
right). Hyper5hmC sites were found to be farther from 
centromeres than from other CpG sites (Wilcoxon non-
parametric test; p = 0.006), although the difference was 
not great (D  =  0.06), whereas we found no significant 
difference in the case of hypo5hmC (Wilcoxon non-
parametric test; p  =  0.23) (Fig.  4b, left). In addition, 
hyper5hmC sites were closer to telomeres than to other 
CpG sites in the array (Wilcoxon non-parametric test; 
p < 0.001 D = −0.15) (Fig. 4b, right).
Following the same methodology outlined above for 
the chromatin studies, we found that both hyper- and 
hypo5hmC CpG sites were associated with the active his-
tone mark H3k4me1. Hypo5hmC sites were also associ-
ated with the repressive histone modification H3K9me3 
(Fig. 5a, b), while hyper5hmC sites were associated with 
the repressive mark H3k27me3 and its methyltransferase 
a b c
d
e
Fig. 3 DNA hydroxymethylation changes in MSCs of two different human age groups. a Box plots showing the Δß levels of both hyperhydroxym‑
ethylated (upper) and hypohydroxymethylated (lower) CpG sites for the young and older groups sampled. b Unsupervised hierarchical clustering 
and heatmap showing the Δß values for the 785 hyper5hmC and 846 hypo5hmC from all the samples. In order to cluster both sites and samples 
the Manhattan distance metric and Ward clustering method were used. Whenever possible, samples are arranged by age. A blue to yellow scale 
is used to represent the Δß values, from 0 (blue) to a maximum value of 0.43 (yellow). In order to enhance the visual representation, negative Δß 
values were set to 0 prior to clustering. c Two dimensional density plot showing the relationship between Δß values of youngest (two years old; 2‑yo) 
and oldest (89 years old; 89‑yo) MSCs. d Examples of two of the aging‑specific d5hmCs, which were further validated by pyrosequencing in eleven 
samples. For each of the genes of interest, a box plot of the percentage of 5‑hydroxymethylation of the CpG site of interest obtained for each sample 
is shown. The gene on the left (VWA2) shows an age‑dependent hypohydroxymethylation tendency, while the gene on the right (KCNQ1) shows 
hyperhydroxymethylation with respect to age. Negative values were adjusted to 0. e Venn diagram showing the overlap of the number of differen‑
tially hyper‑ and hypohydroxymethylated CpG sites and differentially hyper‑ and hypo5methylated CpG sites
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(EZH2) and, to a lesser extent, with H4k20me1 (Fig. 5a, 
b). All associations were statistically significant (Fisher’s 
exact test; p < 0.05).
Finally, we also found statistically significant associa-
tions of both hyper- and hypo5hmC sites with enhancers 
(Fisher’s exact test; p  <  0.05). Interestingly, hyper5hmC 
sites were also associated with repressed genomic regions 
(Fisher’s exact test; p < 0.05) and transcription-transition 
chromatin (Fig. 5c).
Discussion
Previous genome-wide DNA methylation studies have 
shown a gradual decrease in global DNA methylation, 
and increased promoter-associated methylation dur-
ing human aging in most cell and tissue types [6–8]. 
Recently, we also identified age-associated genome wide 
global DNA hypo-methylation changes in MSCs from 
humans of different ages [5].
All these studies were focused on 5mC, a stable cova-
lent DNA modification, but the fact that it can be enzy-
matically converted to 5hmC provides new perspectives 
on the regulatory processes dependent on 5mC pres-
ence (or absence). Thus knowledge of changing DNA 
methylation patterns during aging (as well as under 
pathological conditions) needs to be complemented 
to take into account the contribution of the epigenetic 
mark 5hmC makes to these changes. Information regard-
ing 5hmC in mammalian aging is rather limited: mouse 
cerebellum and hippocampus showed age-associated 
increased 5hmC levels [43], and increased 5hmC lev-
els were observed in developmentally activated genes in 
mice brain during aging [44]. In the main these studies 
involved central nervous system tissues, where 5hmC is 
substantially enriched relative to other tissues and cell 
types: for instance, levels are up to tenfold greater in 
brain than in embryonic stem cells [12, 44]. We there-
fore undertook the analysis of 5hmC DNA content at 
the genome-wide scale, using the same MSCs previ-
ously studied [5], aiming to complete our knowledge of 
DNA methylation changes during human aging in this 
cell type. Concomitantly, we also identified thousands of 
frequently hydroxymethylated CpG sites in the DNA and 
determined their genomic distribution in MSCs.
Furthermore, the possible role of 5hmC in the epige-
netic tuning of enhancer regions has been widely hypoth-
esized [21–25, 30]. These enhancer regions can be found 
in two different states: active, marked by H3k4me1 and 
H3k27ac, and poised, marked only by H3k4me1 [45]. 
Fig. 4 Functional genomic analysis of 5hmC changes in MSCs of two different human age groups. a Left: Violin plot showing the distribution of 
CpG density for hyper5hmCs and hypo5hmC sites against the background sites in the Infinium HumanMethylation450 microarray (Wilcoxon non‑
parametric test; p = 0.23, D = 0.02 and p < 0.001, D = −0.25, respectively). Center: Stacked bar chart showing the relative proportions of CpG sites, 
classified according to their CpG Island status, for the hyper‑ and hypo5hmC sites, and background probe sets. Hyper5hmCs sites are preferentially 
located in CpG Island regions (Chi square test; p < 0.001, OR 1.54), whereas hypo5hmC sites are preferentially located in non‑CpG Island regions 
(Chi square test; p < 0.001, OR 2.09). Right: Stacked bar chart describing the classification of hyper5hmC and hypo5hmC sites and background 
sites according to their relative genomic location. Both are enriched in intergenic regions (Chi square test; p < 0.001, OR 1.51 and p < 0.001, OR 
1.80, respectively). b Violin plots showing the distribution of distances to centromeres (left) (Wilcoxon non‑parametric test; p = 0.006 D = 0.06, and 
p = 0.23 D = 0.02, respectively) and telomeres (right) for the hyper5hmC and hypo5hmC sites and background probe sets (Wilcoxon non‑paramet‑
ric test; p < 0.001 D = −0.16, and p = 0.01 D = −0.01, respectively)
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Our results showed an association of 5hmC CpG sites 
with H3k4me1, but not with H3k27ac, suggesting that, 
in MSCs, 5hmC is preferentially associated with poised 
enhancers. Although this characteristic has also been 
found in previous studies, with both embryonic stem [30] 
and differentiated cells [24], other reports have described 
5hmC as being associated with active enhancers [22, 23], 
and linked it to developmentally important genes that 
can be rapidly activated or silenced [46].
Accumulation of high levels of 5hmC within gene bod-
ies in ESCs [47] and differentiated cells [21, 44] have 
been previously described, and our results confirm 
these 5hmC enrichments in gene bodies, particularly 
in intronic sequences of MSCs. Studies have correlated 
5hmC presence in gene bodies with increased gene 
expression [44, 47], alternative splicing [21], and with a 
depletion of 5mC at the same site [48]. In contrast to the 
well-established role of DNA methylation at promoter 
regions for transcription repression, the function of gene 
body methylation is far from clear: since our previous 
results also showed 5mC depletion on MSCs gene bodies 
with aging [5] it could be, as has already been suggested, 
that 5hmC on gene bodies is a more general epigenetic 
feature, whereas its presence at promoters may be a 
specific feature of pluripotent cell types [46]. Neverthe-
less, while in ESCs the presence of 5hmC in gene bodies 
appears to be consistently correlated with gene expres-
sion [47, 49], the evidence as to whether there is a cor-
relation between promoter 5hmC and transcription is 
inconsistent between studies. Further studies are needed 
to ascertain whether 5hmC is correlated with gene 
expression in MSCs.
A limitation of our study could be its use of different 
methods to obtain the MSCs from the young and older 
groups. It can be assumed that the MSCs obtained from 
the bone-marrow aspirates of the young group come 
mainly from the perivascular niche, while those obtained 
from the bone scrapings of the older group are most 
likely from the endosteal niche. However, no potential 
differences between those MSCs populations have been 
identified to date. Although in this work the two cell 
populations are considered similar, we cannot rule out 
that some of the age-related epigenetic differences seen 
here are due to differences associated with the different 
locations.
It should be also noted that our study was performed on 
MSCs obtained from bone-marrow donors and extended 
under in  vitro culture conditions. It has recently been 
shown that prolonged in vitro culture may affect not only 
5hmc, but also 5mC [50]. That said, our samples were 
obtained at early passages (4–6), so methylation changes 
should not greatly affect our results. However, the rapid 
erasure of 5hmC in mouse embryonic fibroblasts (MEFs) 
and T cells upon cell adaptation to culture systems [51] 
has been described, meaning that our results could be 
an underrepresentation of real levels of 5hmC in MSCs 
in  vivo. In our work, these potential losses of 5hmC in 
MSCs should occur in the same way in samples from the 
two age groups due to culture conditions being the same 
for both simple types. Thus we might assume that the dif-
ferences in 5hmC associated with age described in this 
study may be a reflection of changes in this epigenetic 
mark in regions which remain more stable than others 
when passed to in vitro culture conditions. The fact that the 
genomic distribution of 5hmC (i.e. enrichment in low CpG 
density regions and enhancers, and association with the 
histone posttranslational modification H3K4me1) agrees 
with reports from other experimental settings [21, 24, 25, 
44, 47, 52] does, however, appear to support our findings.
In terms of 5hmC changes between MSCs from dif-
ferent age groups, we found age-associated patterns, 
but without any clear direction of locus-specific 5hmC 
changes attributable to age. The study of the ontologies 
of genes associated with either type of change (hyper- or 
hypo5hmC) showed relationships with biological pro-
cesses related to development, and with cell adhesion 
(See Figure on previous page.) 
Fig. 5 Chromatin signatures associated with DNA hydroxymethylation in MSCs of two different human age groups. a Heatmap showing the rela‑
tive enrichment of the hyper5hmC (upper) and hypo5hmC (lower) sites for a given set of combinations between ENCODE Broad Histone project cell 
lines and histone marks. A red tile is drawn only if the 5hmC sites are significantly enriched for the corresponding combination (Fisher’s exact test; 
p < 0.05). A white to red scale is used to represent the strength of the enrichment, using the base‑2 logarithm of the odds ratio (OR) as a measure of 
shift size. b Upper: Circular layout of chromosomes 1, 4, and 12. Outermost track: Tile chart describing the location of the hyper5hmC and hypo5hmC 
sites. CpG locations were enlarged to 200 kbp regions centered on the site of interest in order to enhance visualization. Middle and innermost tracks: 
Histogram charts showing the peak scores obtained from the Broad Histone UCSC data for H3k4me1 (blue), H3k27me3 (brown) and H4k20me1 
(red) modifications on the HSMM cell line, averaged over 200 kbp regions. Lower: Genome diagrams showing the relative enrichment of H3k4me1, 
H3k27me3 and H4k20me1 marks on three specific regions of chromosomes 17 (left) and 6 (right) with hyper5hmCs sites. c Heatmap showing the 
relative enrichment of the hyper5hmCs (left) and hypo5hmC (right) sites for a given set of combinations between ENCODE Broad ChromHMM 
project cell lines and chromatin states. A tile is drawn only if the 5hmC sites are significantly enriched for the corresponding combination (Fisher’s 
exact test; p < 0.05). Tile colors are chosen to resemble those used in the UCSC representation of the ChromHMM dataset. Intensity of color is used 
to represent the strength of the enrichment, using the base‑2 logarithm of the OR as a measure of shift size
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terms particularly, a very important aspect related to the 
maintenance of stem cell niche, and consequently with 
bone morphogenesis [53–55].
Of note is the fact that CpG sites gaining hydroxym-
ethylation in the advanced age group were those which 
lost 5mC, in accord with previous studies in differenti-
ated cells [24, 44]. This suggests that 5hmC could play 
an influential role in DNA demethylation during aging 
and, therefore, that its behavior with respect to DNA 
methylation should be taken into account along with that 
of 5mC. We have also found that genes associated with 
those probes are related to ontologies of biological pro-
cesses related to development, including several terms 
of morphogenesis, and interestingly, with negative regu-
lation of the cell cycle, which might underlie the loss of 
self-renewal and proliferation previously found in aged 
adult stem cells, including MSCs [55–60]. On the other 
hand, we have found no preferential associations between 
probes which lose 5hmC and 5mC changes, suggesting 
that the former epigenetic mark could have its own role, 
independent of 5mC changes.
A recent study by Yan and collaborators where “adi-
pose-derived” MSCs from older donors were treated 
with the DNA methyltransferase inhibitor 5-Azacy-
tidine evidenced increases in 5hmC which were associ-
ated with decreased 5mC during the process of DNA 
demethylation [60]. Furthermore, this work showed 
that this loss of DNA methylation occurred through the 
induction of TET gene expression [60]. These authors 
also identified a loss of 5hmC together with an increase 
in 5mC during aging of MSCs, which they additionally 
associated with a decrease in proliferation rate and a loss 
of bone differentiation potential. Although we did not 
observe any clear trend of changes in 5hmC over time, it 
should be taken into consideration that Yan and collabo-
rators used immunofluorescent staining, a measure of 
global levels of 5hmC and 5mC (around 27 million CpGs 
in the genome), principally represented by repetitive 
sequences, whilst we performed a genome-wide analysis 
of “bone-marrow-derived” MSCs, and at a locus-specific 
level (<0.5 million CpGs), which included all the genes 
in the human genome. In this way we have identified 
possible functional roles of 5hmC changes in MSCs in 
the developmental process during aging. On the one 
hand we have found increased levels of 5hmC with age 
in genes related to cell adhesion and morphogenesis 
ontologies, decreased levels of 5hmC with age in genes 
related to differentiation ontologies, and increased 5hmc 
in combination with decreased 5mC in genes related to 
proliferation and development ontologies (Additional 
file  1: Table S1, Additional file  2: Table S2, Additional 
file  3: Table S3, Additional file  4: Table S4, Additional 
file  5: Table S5, Additional file  6: Table S6, Additional 
file 7: Table S7, Additional file 8: Table S8). In line with 
this, alterations of these development processes, such 
as impaired bone morphogenesis, decreased prolifera-
tion and osteoblast differentiation of MSCs derived from 
bone-marrow during aging have been described pre-
viously [61–63]. Interestingly, these changes in 5hmC 
occur in chromatin regions marked by H3K4me1, 
H3K27me3 and H3K29me3, which have been previously 
associated with the “stemness” of stem cells [64–69], 
and could therefore be highlighting regions which suffer 
other epigenetic alterations of chromatin associated with 
aging.
The molecular mechanisms by which these changes of 
5hmC occur during aging of MSCs are yet to be deter-
mined. What is clear is that TETs have a key role in these 
processes. The work of Yan and collaborators [60] dem-
onstrated increased expression levels of TET2 in aged 
MSCs, a fact that could be behind the 5hmC changes that 
we observed in our samples given that, as has been shown 
in other cells (i.e. embryonic stem cells), the upregulation 
of TET enzymes is associated with increases in 5hmC 
[70]. In addition, and unlike other methylcytosine oxi-
dases, TET2 has been associated with changes of 5hmC 
in gene bodies [71], as is the case for the hyperhydroxym-
ethylated CpG sites identified in our study.
Finally, other authors have also suggested that the fact 
of both epigenetic marks (5mC and 5hmC) co-existing in 
the genome and the repressive transcription effect of 5mC 
in promoter regions, could point to the role of 5hmC in 
relieving the silencing effect of 5mC by preventing binding 
of methyl-binding proteins [46], apart from its potential 
involvement in demethylation. It could also be that there 
are proteins involved in gene regulation able to bind 5hmC 
specifically, but further work is needed to clarify the role of 
this interesting cytosine modification in the genome.
Conclusions
We identified more than ten thousand CpG sites fre-
quently hydroxymethylated in adult stem cells. We 
showed that, as in other cell types, 5hmC is enriched in 
low density CpG regions, introns, the histone posttrans-
lational modification H3k4me1 and enhancers. We iden-
tified more than 1500 CpG sites showing age-associated 
changes in 5hmC and, most importantly, that many of 
these changes occur in CpG sites that lose 5mC with 
aging, which suggests that 5hmC is an important epige-
netic mark that should be taken into account in studies of 
DNA methylation and aging. In addition, and given the 
importance of MSCs in clinical settings, the age of donors 
should be taken into account since the epigenomic altera-
tions (5mC and 5hmC) which are experienced by the 
epigenome of these cells may affect their potential for 
therapeutic use in the treatment of human diseases.
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